Santen and US ophthalmology company, Eyevance, enter into share purchase agreement
Santen recently announced the acquisition of Eyevance, a US-based ophthalmology company, specialised in the development and commercialisation of topical ophthalmic products targeting the ocular surface and anterior segment. This partnership represents Santen’s first step in creating a strong footprint in the US as a global leader in ophthalmology.
“The acquisition of Eyevance marks another major leap for Santen, which will enable us to contribute to the needs of people impacted by vision-related conditions in the US. This milestone plays an important role towards achieving Vision 2020, Santen’s current long-term strategy, which has guided our evolution from a Japanese-centric business to a specialised company with a global presence across Europe, Asia and now, the US.” – Luis Iglesias, Corporate Officer and Head of Santen EMEA
To access the full press release, please visit the Santen US website.
